Preclinical data also indicate that combining PI3K inhibitors (e.g., copanlisib) with BCR-ABL inhibitors (imatinib) or chemotherapeutic agents (doxorubicin) enhances tumor-cell apoptosis and overcomes drug resistance [31,32]. This evidence concerns the gene ABL1 and neoplasm.